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Abstract  Obesity  has become  a  public  health  problem  around  the world.  According  to  the
Organisation  for  Economic  Co-operation  and  Development  (OECD,  2014  report),  more  than  one
in three  adults  in Mexico  are  obese.  It  is known  that  the  hypothalamus,  a  region  of  the  Cen-
tral Nervous  System  (CNS),  is  actively  involved  in regulating  energy  homeostasis  during  obesity.
Anatomically,  the  hypothalamus  is composed  of  several  nuclei  coordinating  body  weight  and
metabolism,  including  the  arcuate  nucleus  (ARC),  which  contains  neurons  co-expressing  orexi-
genic peptides  like  Agouti-related  protein  (AgRP),  Neuropeptide  Y  (NPY)  and  the  anorexigenic
peptide Pro-opiomelanocortin  (POMC).  During  obesity,  the  integration  and metabolic  response
in the  ARC  is disrupted  by  three  molecular  mechanisms:  (1) activation  of  endoplasmic  reticulum
(ER) stress,  (2)  mitochondrial  dysfunction,  and  (3) increase  of  ER  and  mitochondria  contacts,
known as  Mitochondria-Associated  Membranes  (MAMs).  In  this context,  it  is  proposed  that  MAMs
formation induces  mitochondrial  Ca2+ overload  and  metabolic  dysfunction,  leading  to  insulin
resistance  and diabetes.  Recently,  MAMs  formation  has  emerged  as  one  of  the  molecular  mech-
anisms underlying  metabolic  alterations  during  obesity.  Thus,  in this  review  we  will  focus  on
proposing scientific  evidence  to  support  the role  of  the  MAMs  and  their  function  on  calcium  reg-
ulation  during  obesity,  as  an  important  pathological  mechanism  in the  development  of  diabetes
mellitus type  2.
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Introduction
Obesity  represents  one  of the  diseases  with  the  high-
est  prevalence  worldwide.  The  World  Health  Organization
estimated  that  in 2014  about  13%  of  the adult  popula-
tion  was  obese  and  the  amount  of obesity  in individuals
has  doubled  since  the  1980s.1 In Mexico,  the Organiza-
tion  for  Economic  Co-operation  and  Development  (OECD)
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reported  that  approximately  one  in  three  adults  suffers
from  obesity,2 considering  a  body  mass  index  (BMI)  higher
than  30  kg/m2 to  be  obese.  Usually, an increase  in BMI  is
linked  to  the excessive  intake  of  high  caloric  foods,  or  a
decrease  in catabolism.1--3 However,  this  variable  seems  to
be  multifactorial,  involving  changes  in behavior,  metabolic,
environmental,  genetic,  cultural  and  socioeconomic  factors.
Obesity  increases  the possibility  of developing  cardiovascu-
lar  diseases,  hypertension,  type  2  diabetes,  dyslipidemias,
some  types  of  cancer,  arteriosclerosis  and  cognitive  dete-
rioration,  affecting  the  patient’s  quality  of  life,1,3,4 thus
making  the  understanding  of the  cellular  and  physiological
mechanisms  implicated  in this  pathology  relevant  for  the
development  of  new treatment  approaches.
Compelling  scientific  evidence  suggests  that  the  central
nervous  system  (CNS),  and  especially  the  hypothalamus,
are  key  in the  control  of energy  homeostasis  because  of
their  effects  over  of  food  intake  regulation,  lipid  accumu-
lation  in  the  body  and  body  weight.  Therefore,  defects  in
metabolic  integration  involving  insulin,  leptin  and  ghrelin,
at  a  hypothalamus  level,  generate  alterations  in energy
homeostasis  related  to  the development  of  obesity  and
health  comorbidities.5 The  toxic  effect  associated  with  the
increase  of different  types  of  lipids,  such  as  saturated  fatty
acids  (SFA),  triglycerides  and ceramides  in obesity  is  called
lipotoxicity.7--9 In  this  context,  lipids  are known  to  induce
a  failure  in the  endoplasmic  reticulum  (ER)  and  mitochon-
dria  functions,  promoting  oxidative  stress  in response  to
an  unfolded  protein  response  (UPR)  exacerbation10--12 as
well  as  the  development  of type  2 diabetes  and metabolic
syndrome.6,12--16
At  a  mitochondrial-associated-membrane  level (MAM),
obesity  regulates  the  communication  between  ER  and  the
mitochondria.  In  this  microdomain,  obesity  coordinates  the
recruitment  of proteins  in MAMs  as  well  as  the Ca2+ flow
between  ER and  mitochondria  at  the hypothalamus  and  liver
level.17--19
In this  review,  we  will  discuss  the  role  of the  hypothala-
mus  in  the  regulation  of  energy  consumption  and  its  effect
on  obesity  and diabetes  development  in the context  of  MAMs
remodeling,  alterations  in Ca2+ homeostasis,  activation  of ER
stress  and  mitochondrial  function.
The hypothalamus  is a brain  region  which  is
key in  the control of  energy homeostasis
The  hypothalamus  is  part  of the diencephalon,  located  under
the  thalamus  and  formed  by  different  nuclei.  Prominent
among  these  are the  preoptic,  paraventricular,  suprachias-
matic,  lateral,  posterior,  mammillary,  dorsomedial  (DMH),
ventromedial  (VMH)  and  arcuate  (ARC).  As  a  whole,  the acti-
vation  of  the different  nuclei  regulates  energy  homeostasis
through  their  action  over  food  intake,  thermogenesis,  and
glucose  balance  in  plasma,  among  other  things.20 In  par-
ticular,  DMH,  VMH,  ARC,  the  medial  portion  of the  lateral
hypothalamus  and the ventral  premammillary  nucleus  are
related  to  the  regulation  of  food  intake.  Therefore,  they
are  called  the  ‘‘satiety  center’’,  while  the  lateral  hypo-
thalamus  represents  part of  the  ‘‘feeding  center’’.20--22,25
All  these  hypothalamic  nuclei  are  part  of  an integral  system
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Figure  1 The  arcuate  nucleus  neurons  (ARC)  Neuropeptide
Y/Agouti  related-proteins  (NPY/AgRP)  and  propiomelacortics
(POMC)  coordinate  the  activity  of  the  paraventricular  (PVN)
nucleus,  promoting  the stimulation  or inhibition  of  apetite,
respectively.  GABA  is  a  neurotransmitter  released  by  the
NPY/AgRP  neurons,  and  is very  important  to  the  control  of  food
intake, inhibiting  the  anorectic  effects  of  the  POMC  neurons.
called  the melanocortin  system  which  modulates  with  the
regulation  of  energy  and  satiety.
The  nuclei  which  form  a  part  of  the melanocortin  system
possess  selective  specificity  for  synthesis  and  the  libera-
tion  of  neuropeptides  and  neurotransmitters  according  to
their  cellular  type  identity.  Thus,  ARC  is  formed  by  orexi-
genic  neurons  which  express  the Neuropeptide  Y  (NPY)/the
agouti  related  peptide  (AgRP),  anorexigenic  neurons,  and
proopiomelanocortin  (POMC),  which  release  POMC.  The  lat-
ter  is  processed  into  a  melanocytes  -stimulating  hormone
(MSH).  NPY/AgRP  and  POMC/MSH  increase  and  decrease
respectively,  in appetite.22--24 It  is  known  that  the great-
est  concentrations  of  neurons  expressing  insulin  receptors
is  located  at the  ARC  level.  ARC  and its  fibers  project  to  the
paraventricular  nucleus  and  periformical  region  (Fig.  1).23
Arc  is  found  in a  privileged  position  within  the  hypothala-
mus  since  its  proximity  to  the  median  eminence  (ME)  allows
it  to  sense  hormonal  and  biochemical  factors  of  blood  and
cerebrospinal  fluid  with  the  purpose  of  regulating  energy
homeostasis,22,23,25 among  which  leptin,  insulin  and  ghrelin
stand  out. Leptin  and  insulin, secreted  by  adipocytes  and  the
pancreas  respectively,  produce  anorexigenic  effects through
their  action  over  ARC,  producing  leading  to  an increase  in
the genetic  expression  of NPY/AgRP  and  a decrease  of  POMC
in ARC,23,24,26,27,29,30 while  ghrelin,  secreted  by the  stom-
ach,  promotes  food  intake31,32 through  the stimulation  of
the  GHSR1  receptor  in ARC’s  NPY/AgRP  neurons,  inhibiting
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its  activity  through  the  action  of the gamma  aminobutyric
acid  (GABA)  neurotransmitter.33--35
Obesity promotes generation of insulin  and
leptin resistance
In  animal  models  of  obesity,  induced  by  high-fat  diet intake
or  in  obese  patients,  the presence  of  insulin  and  leptin
resistance  has  been  demonstrated.  Insulin  resistance  is  a
key  factor  in the development  of  type 2  diabetes  mellitus
(DMT2).36 Physiologically,  the  effects  of  insulin  resistance
are  known  to  be  manifested  in  the pancreas,  muscle  and
hypothalamus.  Glucose  homeostasis  in the  body  is  main-
tained  due  to  the action  of insulin  on  adipocytes  and  muscle.
At  first,  the  pancreas   cells  release  insulin,  which  binds to
its  receptor  on the adipocytes  and  hepatocytes,  and pro-
motes  the  translocation  of  vesicles  from  the  cytoplasm  to
the  plasmatic  membrane  containing  GLUT-4  transporter.37
Molecularly,  insulin  attaches  to  the   subunit  of  the insulin
receptor  (IR),  inducing  the activation  of  the tyrosine  kinase
domain  in  the intracellular  portion  of  the   subunit38 and
the  phosphorylation  of  three  tyrosine  residues  (Tyr-1158,
Tyr-1162  and  Tyr-1163).38 The  signal is amplified  through  the
downstream  phosphorylation  insulin  receptor  substrate  type
proteins  (IRS-1,  IRS-2,  IRS-3,  IRS-4),  recruiting  Shc,  growth
factor  2  (Grb2/SOS)  and  regulatory  subunit  p85 of the ino-
sitol  phosphatidiyl  3′-kinase  (PI2  kinase).38--42 Amongst  all
these,  PI3K  plays  a major  role for  the activation  of  the
Akt/PKB  and  PKC cascade.  Once activated,  the Akt  pro-
tein  induces  glycogen  synthesis  through  the inhibition  of
the  glycogen  synthase  kinase  protein  (GSK-3),  the  synthesis
of  mTOR  (mammalian  target  of  rampamycin)  core  protein
and  cellular  survival  by  the  inhibition  of  the apoptosis.39--42
However,  in insulin-resistant  conditions,  such  as  the ones
presented  during  lipids  increase  in  obesity,  phosphoryla-
tion  is  inhibited  in IRS1  tyrosine  and increasing  307 serine
phosphorylation  of IRS1.37,43 Pancreatic  cells  respond  by
upregulating  the synthesis  and liberation  of  insulin  leading  to
  cells  dysfunction  and  DMT2  development.44 On the  other
hand,  obesity  also  induces  insulin  resistance  in  the hypo-
thalamus,  where  the  decrease  in the number  of  receptors
to  this  hormone  is  observed.45,46 Altogether,  hyperglycemia
during  obesity  is  linked  to  alterations  in:  (1)  decrease  in
tyrosine  phosphorylation,  (2)  decrease  in  the number  of
receptors  to  insulin,  and (3)  increase  in the plasmatic  levels
of  insulin.  Furthermore,  an increase  in  blood  leptin  con-
centrations  has  been  demonstrated  as  a leptin-resistance
index  in  obese  patients  and  obesity-induced  murine  models
by  high-fat  diet  intake.28 Leptin  signalling  pathway  is  acti-
vated  by  leptin  binding  to its  receptor  and the downstream
activation  of  Janus  (JAK)  kinases by  transducers  and acti-
vators  of  transcriptions  (STAT),  MAPK and  IRS1.47,48 In the
context  of  obesity,  leptin  resistance  is  linked  to  the reduced
activity  of  the  transductor  and  the  phosphorylated  activa-
tor  of  transcription  3 (STAT)48,49 and  to  the no-activation  of
genes  of  the cytokine  suppressors  family (SOCS).49 In  fact,
it  has  been  recently  demonstrated  that  leptin  and  insulin
act  as  a  whole  on  hypothalamic  neurons,50 suggesting  that
obesity  affects  hypothalamic  circuits  and  compromises  the
hormonal  integration  implicated  in the coordination  of  ener-
getic  metabolism.
Additionally,  the effect  of  these  hormones  on  body  phys-
iology  not only  relates  to  obesity  problems,  but  also  to  the
development  of hypertension  in mice  and  humans51--53 and
Alzheimer’s  susceptibility.54 Thus,  the mechanisms  which
underlie  the  functional  alterations  of  the  hypothalamus  dur-
ing  obesity  might  be implicated  in additional  pathologies  in
humans.
Alterations in the  endoplasmic  reticulum  and
mitochondria function during obesity promote
insulin and leptin resistance
Different  studies  have provided  substantial  evidence  that
obesity  induces  endoplasmic  reticulum  (ER)  stress  and mito-
chondrial  dysfunction  into  organs  which  are metabolically
relevant  for  the coordination  of  energetic  balance.  ER is  a
network  of  membranous  tubes  and  flattened  sacs  which  is
present  in all  eukaryotic  cells,  involving  synthesis,  folding,
maturation  and traffic  of  proteins,  as  well  as  storage  and
homeostasis  of  Ca+2 and  lipid  biosynthesis.12,15,55,56 Proteins
enter  into  the ER  lumen  as  unfolded  polypeptide  chains  and
they  fold  in  the  interior  to  make a  more  stable  formation.
When  the proteins  are misfolded,  they overload,  and  the
expression  of  chaperones  is  activated  with  the inability  to
control  its  accumulation,  with  the  objective  of  stimulating
the  unfolded  protein  response  (UPR).  Protein  synthesis,  and
its  translocation  toward ER,  are  reduced  in this  process,  and
UPR  genes  are  activated  to  increase  the  ability  of ER  to  fix
misfolded  proteins.  If  homeostasis  cannot  be reestablished,
a mechanism  of  cell death  by  apoptosis  is  stimulated.12,15,57
This  regulation  mechanism  is  very  active  and  especially
important  in secreting  cells41 such as  neurons.11
ER’s  stress sensors and UPR onset
The  increase  of  misfolded  proteins  in ER  is  well-known  to
produce  stress,  which may  be measured  by  select  mem-
brane  protein  groups  called:  IRE,  PERK  and  ATF6.58,59 Ire1,
as  well  as  Ire1, break  the ARNm  of  the X-box  binding  protein
(XBP1)  generating  XBP1  splicing  (sXBP1).59 sXBP1  activates
the  expression  of  genes  which  codify for  the synthesis  of
chaperones,  components  of  the  degradation  of ER  associ-
ated  with  protein  degradation  (ERAD)  and genes  in charge
of  phospholipid  biosynthesis  and  autophagy.60--62 The  PERK
complex  phosphorylates  the  translation  initiation  factor
eIF2a,  dimming  translation,  yet  boosting  ATF4  translation,
which  regulates  genes  with  secretor  functions  and of the
apoptotic  type  included  in  the  C/EBP  homologous  (CHOP)
protein.60,62 ATF6  is an activator  factor  which  travels  to  the
Golgi  apparatus  in response  to  stress,  where  it undergoes
proteolysis,  liberating  its  cytosolic  domain,  called  the  bZip
transcription  factor,  which  enters  the nucleus  and  activates
the  UPR  genes  involved  in protein  folding,  processing  and
degrading.60 The  chaperones  which regulate  the  proper  pro-
tein  folding  are the proteins  related  to  GRP78  glucose,  also
known  as  heavy  chain  binding  immunoglobulin  proteins,58
protein  disulfide-isomerase  (PDI),  calnexin  (CANX),  calreti-
culin (CALR)  and  GRP94.59 In this context,  BiP  binds  to Ire1,
ATF6  and  PERK  domains  and  dissociates  after  ER  stress  induc-
tion,  suggesting  that  unfolded  proteins  compete  for  BiP,
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Figure  2  Misfolded  Protein  Response  (MPR).  When  the flow  of  misfolded  proteins  to  the ER  is  increased,  the  BIP  protein  chaperone
is released  from  IRE-1,  PERK  and  ATF6,  allowing  it  to  act  as  a  transcription  factor  and allowing  chaperone  proteins  synthesis,  which
improve protein  folding.
allowing  the  oligomerization  and  activation  of  these  sensors
(Fig.  2).51,60,61
Lipid  accumulation during obesity creates ER
stress inducing  hypothalamic inflammation
and the generation of diabetes
Epidemiological  data  confirms  a strong  link  between  the
increase  in  the level  of  obesity  and the  development  of
type  2 diabetes;  indicating  that  for  every  kilogram  of  gained
weight,  at  the population  level,  there  is  a linear  increase  in
the  diabetes  rate.3 Experimental  evidence,  in  obese humans
and  animal  models  with  obesity,  suggests  that the  escape
of  lipids  from  adipose  tissue  and  ectopic  accumulation  of
ceramides  (a type of sphingolipid),  acylcarnitines,  diacyl-
glycerols  and AGS  cause  tissue  damage  to  metabolically
relevant  organs,  including  the  skeletal  muscle,  liver,  pan-
creatic  beta  cells,  myocardium  and  brain,  in  an event  called
lipotoxicity.63--65 The  lipotoxic  effect  is  largely  determined
because  every  organ  has its  own  lipid  profile.  Hence, selec-
tive  changes  in lipid  species  in different  organs  may  be
relevant  to  the development  of  lipotoxicity.  In  this context,
it  is known  that,  physiologically,  C18:0  type ceramides  are
essential  for  cerebellar  development  and  C22:0-24:0  regu-
lates  hepatic  function,63,64 while  saturated  diacylglycerols
and  lipids  take  part  in intracellular  signaling  processes  in
many  cellular  types  of  the body.65 In  this regard,  it  has  been
suggested  that  during  obesity  new  species  of  lipids,  which
are  potentially  toxic  for  the body’s  organs,  are produced,
including  ceramides,  cholesterol,  AGS  and diacylglycerols.
All  these species  are  known  to  inhibit  insulin  sensitivity  in
cellular  cultures  and  animal  models.66 Saturated  ceramide
and  lipid  accumulation  has  even been  detected  in the
skeletal  muscle  of  obese  humans,  which  correlates  to  a
generation  of  insulin  resistance.66,67 Of  note,  ceramides,
cholesterol,  saturated  DAG  and lipids  activate  the ER’s  stress
in the hypothalamus  in animal models,  generating  insulin
resistance.9,11,66,68
Notably,  a  close  connection  is  known  to  exist  between  the
ER  stress  activation  and  inflammation.  Experimental  work
shows  that  Jun-N  terminal  kinase  (JNK  activating  protein  1
--  AP1-),  activated  during  the  ER’s  stress  promotes  the  activ-
ity  of  the IKKB/NF-B  pathway.69 De Sousa  et  al. (2005),
proved  that  high  fat  diet-induced  obesity  increases  the  TNF
levels  and  other  pro-inflammatory  cytokines  in serum  of
animal  models  of  obesity.45 In  contrast  with  unsaturated
lipids,  intra-cerebrovascular  infusion  of saturated  lipids  and
palmitic  acid  cause  inflammation  and  insulin  resistance,
which  is  a  IKK-kinase  dependent  pro-inflammatory,70 pre-
sumably  through  the activation  of TLR4 recetors.71,72 In
this  context,  the  increase  of  SFA,  cholesterol,  triglycerides,
DAGs  and  ceramides  during  obesity  causes  the activation
of  ER stress  and  inflammation,  inducing  the  insulin  resis-
tance  state  in the hypothalamus  and generating  metabolic
complications.
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Lipotoxicity linked to lipid  increase  during
obesity produces  mitochondrial dysfunction,
insulin resistance and the development of
diabetes
Mitochondria  represents  pivotal  intracellular  organelles  in
charge  of  ATP  synthesis  through  oxidation  of  energetic  sub-
strates  and  cellular processes,  including  cell  differentiation
and  cellular  death,  and  help  maintain  growth  control  and
the  cellular  cycle.73 Defects  in  mitochondrial  function  leads
to  a  metabolic  deterioration  increasing  susceptibility  to  the
development  of  type  II diabetes  mellitus  or  obesity.74
Different  studies  on the  muscle  of  obese humans  with
a  insulin  resistance  state  have  shown  that  the  presence
of  mitochondrial  dysfunction,  including  low oxidative  enzy-
matic  activity  and  a decrease  in  lipid  metabolism  compared
to  thin  subjects.75 Furthermore,  SFA  increase  during  obe-
sity  correlates  with  primary  defects  of  the mitochondrial
oxidative  capacity  of  the  muscle,  liver  and  adipose  tis-
sue,  promoting  DAG  increase  and  insulin  resistance.76 These
events  are  closely  linked with  the increase  in T2DM.73,77
A  big  part  of the  lipotoxic  effect  of lipids  over  the  mito-
chondrial  function  is  because  its  accumulation  produces
reactive  oxygen  species  (ROS),  including  anion  superox-
ide  (O2−),  hydrogen  peroxide  (H2O2) and hydroxyl  radical
(OH−).73 A  fatty  dietary  intake  in mice  has  been  proven
to  increase  ROS  production  in  the liver  and  adipocytes
and  precedes  TNF  increase  in blood  and  liver.78 A sim-
ilar  effect  has  been  found in the hypothalamus  of  rats
with  acute  hypertriglyceridemia,  caused  by  intraperitoneal
or  intra-cerebrovascular  injections  of  20%  lipids  including
a  combination  of  soy  oil,  glycerin  and  phospholipids.79 In
this  context,  we  were  able  to  demonstrated  the lipotoxic
neuronal  damage  at metabolic  center  regulator  caused  by
the  injections  of lipids  and promoting  the  consumption  of
food.79 This  effect  seems  to  be  linked  to  ROS  increase  in
the  POMC  neurons  of the  hypothalamus,  which  produce
satiety,  hence  the suggestion  that  POMC  neurons  are more
sensitive  to  lipotoxic  damage  caused  by  ROS  compared  to
NPY/AgRP  neurons.  Conversely  to  these  events,  the  admin-
istration  of  complex  antioxidants  prevents  ROS  formation
and  inhibits  appetite,  in part by  inducing  the expression
of  POMC  in ARC.80 Consequently,  mitochondrial  dysfunction
linked  to  the  development  of obesity  modulates  food  intake
and  sensitivity  to  insulin,  coordinating  the development
of  T2DM.
By  now,  the  cause  of  mitochondrial  damage  during  obe-
sity  and  its effect  on  insulin  sensitivity  is  unknown.  In
fact,  mitochondrial  dysfunction  is  proposed  to  be  a  con-
sequence  and  not  a cause  of  insulin.  This  is  based  on  the
fact  that  alterations  in the  mitochondrial  function in diverse
models  do  not  decrease  insulin  sensitivity.81 Even  the lipid
infusion,  which  promotes insulin  resistance,  increases  beta
oxidation  in  humans  and,  contrarily,  an increase  in insulin
sensitivity  by  sensitizing  agents  (metformin,  TZD,  among
others)  inhibits  ATP production  in the  mitochondria.81 In any
case,  accumulated  experimental  evidence  during the last
decade  of  research  have  give  us substantial  support  propos-
ing  that  mitochondria  seems  to  coordinate  the development
of  metabolic  complications  linked  to  obesity,  either  promot-
ing  or  inhibiting  lipotoxic  damage.
Certainly,  it  is  necessary  to  conduct  further  integral
research,  which  will  determine  whether  or  not  mito-
chondrial  dysfunction  during  obesity  is  a cause  or  the
consequence  of the  metabolic  imbalance  which  facilitates
the  development  of  T2DM  in humans.
Lipids accumulation during obesity modulate
MAMs formation and coordinate the
development of  diabetes
ER  and the mitochondria  interact  metabolically  and  func-
tionally  through  links  between  its membranes  known
as MAMs.82,83 Its  function  has been  related  to  ER’s
phospholipids  import  to  the  mitochondria,  the cellular
response  between  the  ER and mitochondria,  and cell
survival  and  death.17,84 MAMs  constitute  a microdomain
which recruits  different  proteins  of  functional  impor-
tance,  among  them:  (1)  enzymes  which  participate  in the
synthesis  of  lipids  (acyltransferase  cholesterol,  diacylglyc-
erol  acyltransferase  and  phosphatidylserine  synthase),84
(2)  calcium-regulator  proteins  (inositol-1,4,5-tris  phosphate
receptor  (IPR),  ryanodine  receptor  (RyR),  the  voltage-
dependent-anion-mitochondrial-channel-1protein  (VDAC1)
and  the sigma-1receptor  (SigR1)),  (3)  proteins  which  par-
ticipate  in protein  folding  (calnexin  (CNX) and ERO  1L-),84
(4)  proteins  involved  in mitochondrial  remodeling  (dynamin-
like  1  (DPR1)  and  mitofusins  1  and  2 (MFN  1  and  2)),  and  (5)
the  ER binding  stabilizing  proteins,  PACS2  (Fig.  3).84
The  interaction  between  ER  and  the mitochondria  has
been  recently  proven  to  be regulated  by  the  action  of
MFN  1  and  2  (Fig.  3).84 It has  been  proven that  fibro-
blasts  which  do  not  express  MFN2  display  a reduction  in
the contacts  between  ER  and the  mitochondria,  which
recover  when the MFN2  expression  is  reestablished  in
ER  through  genetic  manipulation.85 Functional  integration
through  MAMs  allows  calcium  homeostasis  regulation  in
the  cell.  In  base  conditions,  Ca2+ concentration  in the
cell’s  cytosol  (free  100  nM  Ca2+ versus  100  mM in extra-
cellular  space)  is  maintained  through  active participation
of  the ER and  the  mitochondria.  Cytosolic  Ca2+ is  cap-
tured  to  the  ER  by  the action of  the SERCA  bomb  and  is
taken  by  buffering  molecules  such  as  calsequestrin.86 Under
stimulation  conditions,  Ca2+ is  released  from  ER  by the
ryanodine  receptor,  activated  by very  low cytosolic  Ca2+
concentrations,  or  through  IP3R  receptors  (abundantly  con-
centrated  in  MAMs)66 in response  to  phosphatidylinositol
signals,  produced  when  Ca+2 concentrations  are  low.86 Ca2+
released  through  IP3R  flows  to  the mitochondrial  matrix
through  mitochondrial  calcium  uniporter  proteins  (MCU),82
activating  mitochondrial  dehydrogenases  activity  which are
a  key  element  in ATP  production.82,87 Nevertheless,  an
increase  in  ER’s  calcium  flow  to the  mitochondria  through
IP3R  promotes  mitochondrial  damage and  apoptosis.87 In
fact,  MFN1,  MFN2,  phosphatidylinositol-3,4,5-triphosphate
3-phospatase  (PTEN),  promyelocytic  leukemia  (PML)  and  RE
L-  oxydoreducin  chaperone  proteins  (ERO-1  L-) increase
ER  calcium  release  to  the  mitochondria,  either  phosphory-
lating  or  interacting  with  IP3R.88--92
Calcium  decrease  at  the ER  level  creates  ER  stress
activation,  including  morphologic  changes  and an  ER-
mitochondrial  bind  increase,93 leading  to  an increase  in
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Figure  3  The  Mitochondria-Associated  Membranes  (MAMs)  are  a  microdomain  made  up of  different  proteins  which  are in charge
of calcium  homeostasis,  transport  of  lipids,  mitochondrial  morphology  and  the  oversight  of  cellular  death.  Their  work  has  recently
been associated  with  the  coordination  of  energetic  metabolism.
mitochondrial  activity.93 It has  been noted  that  defects  in
MAMs  microdomains’  proteins  have  been  proven  to  promote
ER  stress  previous  to  the  development  of mitochondrial
dysfunction.41 This  way,  it is  possible  for  defects  in the
conformation  of  MAMs  to  lead  to  alterations  in calcium
homeostasis  or  metabolic damage  linked  to  ER  stress,  induc-
ing  a  mitochondrial  dysfunction.  In  this context,  MFN2
deletion  in  rats and mice  promotes  insulin  resistance  and
mitochondrial  dysfunction  linked  to  ER  stress  activation  in
skeletal  muscle77,94 and  liver95,96 and a  decrease  in MTF2
expression  was  proven  in obese  patients.  It  is  worth  stressing
that  obesity  induced  by  high-fat  dietary  intake  in mice  who
lacked  MFN2  in anoerxigenic  POMC  neurons  of  the hypothal-
amus,  created  a  decrease  in  ER  and mitochondria  contacts,
resulting  in ER  stress, leptin  resistance  and a reduced  energy
expenditure.17 Contrarily,  obesity  induced  by  a  high-fat  diet
intake  in  mice  who  lacked  MFN1  and  MFN2  in AgRP  orexi-
genic  neurons  of  the  hypothalamus  promoted  a  decrease  in
ER  and  mitochondria  contacts,  obesity,  and  increase  in par-
tial  fat.18 Molecularly,  it is  suggested  that  an increase  in ER
and  mitochondria  contacts  coordinated  by  MFN2  during  obe-
sity,  increase  Ca2+ flows  from  ER  to  the  mitochondria  through
IP3R  receptors,  generating  mitochondrial  dysfunction,  acti-
vation  of  the  JNK  pathway  and insulin  resistance19 (Fig. 4).
All  together,  it seems  that  MAMs  closely coordinate  energy
metabolism  through  their  defects  over calcium  homeostasis,
ER  activation  and  mitochondrial  function,  molecular  pro-
cesses  which  are  compromise  during  lipotoxicity  induced  by
lipids  accumulation  during  obesity.97
Strategies for obesity treatment and  its
effects in patients
Given  the  effect  of  obesity  in the development  of  comorbidi-
ties,  different  strategies  have  been  used with  the purpose
of  inducing  weight  loss  and  its  effect  on  the improvement
of  glycemic  control  in obese  subjects  with  T2DM.98,99 How-
ever,  keeping  the  weight  off  represents  a  greater  challenge
in  obesity  treatment.100 To  this end,  different  interventions
have  been  employed,  such  as  diets,  pharmacological  treat-
ments  and  surgery.  As  an example  of the  first  intervention,
in  a  meta-analysis  study  using  data  from  the Cochrane  Cen-
tral Register  of  Controlled  Trials  and  EMBASE  from January
1981  to  February  2013,  anti-obesity  drugs,  food  replace-
ment  and  high-protein  diets  were  proven  to be  linked  to
weight-loss  maintenance  compared  to food  supplements
and  exercise.100 On  the  other  hand,  pharmacological  treat-
ment  has  not  been  so  successful,  in part  due  to  its  limited
success  in  the long  term  and  lack  of effect  when  the con-
sumption  is  stopped,  also  the development  of  major  side
effects.101,102 One  example  in this  scenario  is  the  Fen-
Phen  (Fenfluramine/phentermine,  serotonin/noradrenaline
releasers),  withdrawn  from  the market  in 1997 because  of
its  side  effects,  which  included  valve  disease  and  pulmonary
hypertension,  and  rimonabant  (CB1  receptor  antagonist),
withdrawn  from  the  market  in 2008  because  of  its pos-
itive  effect  on  the  generation  of severe  depression  and
suicides.101 As  a third  intervention,  there  is  bariatric  surgery,
which  has  proven  to  be effective  in weight  loss  and  even
remitting  T2DM  or  improving  glucose  levels  in patients  for
over  two  years.103 We will  now  describe  the effect  of
said  intervention  on  the nervous  system  for  the control  of
metabolism.
Bariatric surgery  and its  effect on the  CNS  for
promoting weight loss
It is  well-known  that  not all patients  who  lose  weight  in
the obesity  context  are able  to  keep  the weight  off in
the long  term.  For example,  in the US,  approximately  1
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Figure  4  The  development  of  obesity  promotes  an  increase  in between  ER  and mitochondrias  contacts  in  the  liver,  leading  to
mitochondria Ca2+ overload  and  oxidative  damage  and  inflammation  generation.
in every  6 subjects  can maintain  the loss  of  10%  weight  in
the  long  term,  the rest  suffer  a  relapse  and continue  to  be
at  risk  of  T2DM  generation.104 Since  its  beginnings  in the
50s,  bariatric  surgery,  including  Roux-en-Y  gastric  bypass
(RYGB),  adjustable  gastric  band  (AGB)  and  biliopancreatic
diversion  have  been  the most  effective  interventions  for  the
treatment  of obesity  in  a  population  with  morbid  obesity
(BMI  ≥40  or ≥35).105,106 These  surgeries  allow  weight  loss
through  caloric  restriction  and/or  malabsorption  of  calories
and  reverts  or  reduces  comorbidities  like  T2DM,  hyperten-
sion  and  hyperlipidemia,  among  others.105,107
Interestingly  enough,  the  effect  of  bariatric  surgery
intervention  has  over the nervous  system’s  ability  to  reg-
ulate  the  metabolism  of the  body  has recently  been
demonstrated.  Studies  have shown  high  activity,  specifically
in  the  hypothalamus  region  of  the brain  of  women  who  have
undergone  RYGB  surgery  when  they  are shown  images  of
hyper-caloric  food,  regarding  non-obese  women,  which  cor-
relate  with  a  low score  in hunger  and a  high  score  in satiety
compared  to  those  with  normal  and  obese.108 Molecularly,
the  melanocortin  4 receptor  (MC4R)  has been  proven  to  be
a  target  responsible  for  weight  maintenance  in  individuals
who  are  heterozygous  for  this gene.109
Also,  even  though  bariatric  surgery  allows  for  the  reduc-
tion  of  body  weight,  its  effect  in the long  run depends  in
large  part  on obese  subjects.  The  reason  for  this  effect  may
be  linked  to  a change  in hormone  liberation  from  the  intes-
tine  and  stomach,  which  regulates  the  body  metabolism.
RYGB  and  VSG  bariatric  surgeries  are  known  to  increase  the
release  of  pepri  YY  (PYY),  released  by  L cells  from  the  distal
small  intestine,110,111 but  it  does not have  an effect  during
caloric  restriction  or  due  to  a  gastric  band  surgery.106,112,113
Weight  loss  is  greater  in patients  who  underwent  RYGB
surgery  and  who  present  an  increase  in  PYY.114,115 PYY  has
an  anorexigenic  effect,  acting  at a  solitary  tract nucleus  and
ARC  level116 to  promote  an increase  in energy  expenditure
and  delay  stomach  emptying.117 Another  peptide  secreted
by  L cells  is  GLP-1  (glucagon-like  peptide-1),  which inhibits
glucagon  release  and  slows  gastric  emptying,  also  reducing
food  intake  by  stimulating  the hypothalamus  and  brain  stem
hormones,  among  other  regions  of the brain  like  striatum
and  black  matter.106,118 GLP-1  has  shown  similar  responses
to  PYY  after  RYGB  and  VSG  surgeries.106,119A third hormone
which  suffers  changes  after gastric  surgery  is  ghrelin,  which
is released  from  the stomach  and inhibits  food  intake,  induc-
ing  the activation  of the  hypothalamus.  Ghrelin  is  reduced
after  VSG  surgery,120 increases  after  gastric  band  surgery
and  remains  without  changes,  increases  or  decreases,  after
RYGB.106,121,122
Finally,  basic  science  experiments  have  shown  non-
conclusive  target  results  additional  to  the  effect  of  the
bariatric  surgery  over  the  nervous  system  function.  Among
them,  reports  suggest  that  there  are not any  changes  in
the neuropeptide  expression  which  promotes  food  intake,
including  AgRP  and NPY,123 while  other  reports  show
a  decrease  in NPY  expression,124 or  an NPY  and  AgRP
increase.125 All  together,  more  evidence  is required  to  con-
clusively  determine  the effect  of  bariatric  surgery  over body
weight  regulation  through  the anorexigenic,  orexigenic  neu-
ropeptides  and  GLP-1  function  expressions  in the  CNS.
Possible strategies  for  MAMs remodeling as
obesity treatment
One  of  the most  outstanding  pharmacological  strategies  to
control  lipotoxic  damage  induced  during  obesity  is  the  use
of  chemical  chaperones.  Chemical  chaperones  are agents
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which  avoid  ER  stress  and  improve  mitochondrial  func-
tion.  These  chaperones  produce  changes  in  MAMs  proteins,
lowering  of the  binds  between  ER  and the mitochon-
dria,  the  increase  of oxidative  stress  and Ca2+ flow  to
the  mitochondria.19 In mice  models,  chemical  chaperones
including  4-phenyl  butyric  acid  (4-PBA),  a  low-molecular-
weight  molecule,  and  taurine  ursodeoxycholic  conjugate
acid  (TUDCA),  an endogenous  biliary  salts  derivate,16 and
R, S-O-(3-piperidino-2-hydroxy-1-propil)-dihydrochloride  of
amidoxime  nicotinic  acid  (BGP-15),  have shown  to  be effec-
tive  in  protecting  against  the  ER stress  activation  favoring
insulin  sensitivity.  In  this  context,  results  in cellular  culture
as  well  as  in genetic  animal  models  of  obesity  (mice  ob/ob),
have  show  that  chaperones  reduce  ER  stress,  normalize  glu-
cose  levels  and  increase  insulin  sensitivity.16 In particular,
BGP-15  is  the  most  promising  candidate  to  improve  insulin
sensitivity,  since  it  is  comparable  to  other  insulin  sensitizers
tested,  like  rosiglitazone,126 in addition  to  having  effects
in  patients  with  diabetes.127 Other  new  drugs  which  mod-
ule  ER  stress  response  are being  tested  in  animal  models,
such  as  celastrol,  which is  a molecule  extracted  from  the
Tripterygium  wilfordii  plant  that  reduces  ER  stress  and acts
as  a  leptin  sensitizer,  and has  great  potential  as  anti-obesity
therapeutic  agent.128
Even  though  it  has  not been  proven  in humans,  evi-
dence  suggests  that  protein  modulation,  which comprises
the  MAMs  microdomain,  may  be  a  therapeutic  target  to
improve  metabolism  and reduce  oxidative  stress  and the
inflammatory  response  observed  in obesity.129
Conclusions
POMC  and  AgRP neurons  of  the ARC  nucleus  of  hypothala-
mus  represent  a functional  node  which  regulates  corporal
energy  homeostasis  and  is the target  of  pathological  alter-
ations  during  obesity  which  predispose  to  the  development
of  diabetes.  One  of  the most significant  alterations  caused
by  obesity  is  the  increase  of  lipids,  which generates  changes
in  MAMs  proteins  recruitment  and  spatial  conformation,  pro-
moting  ER  stress  and  an increase  in calcium  flow  between
ER  and  the  mitochondria.  ER  stress  activation  is  known
to  be  linked  to  ROS  increase  and  inflammation,  which in
turn  promotes  the development  of insulin  resistance,  glu-
cose  intolerance  and  diabetes.  A  strategy  to  revert  these
alterations  is  through  bariatric  surgery,  since  it promotes
changes  in  hormones  released  in  the intestine  like  PYY,  ghre-
lin  and  GLP-1.  Another  strategy  which may  be  available  in
the  future  for obese  patients  is  chemical  chaperones,  which
lower  ER  stress  and  improve  insulin  and  leptin  sensitivity.
We  suggest  that  changes  or  alterations  in MAMs  remodel-
ing  represent  a  pathological  mechanism  in the context  of
obesity,  where  molecular  systems implicated  in ER stress
activation  and  mitochondrial  function  contribute  to  the  con-
trol  of  metabolic  homeostasis.  Thus,  thoroughly  addressing
the  characterization  of  MAMs  microdomain  may  enable  us to
find  new  therapeutic  targets  for  obesity  treatment.
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